Advice

in the absence of a submission from the holder of the marketing authorisation

ceftaroline fosamil (Zinforo®) is not recommended for use within NHS Scotland.

Indication under review: treatment of 

• complicated skin and soft tissue infections in children from the age of 2 months 
• community-acquired pneumonia in children from the age of 2 months

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting.  As a result we cannot recommend its use within NHSScotland. 

SMC has previously issued accepted ceftaroline fosamil for restricted use in adults with known of suspected meticillin resistant Staphylococcus aureus (MRSA) skin and soft tissue infection and this advice remains in place. 

Download detailed advice149KB (PDF)

Download

Medicine details

Medicine name:
ceftaroline fosamil (Zinforo)
SMC ID:
1306/18
Indication:
treatment of complicated skin and soft tissue infections in children from the age of 2 months • community-acquired pneumonia in children from the age of 2 months
Pharmaceutical company
Pfizer Ltd
BNF chapter
Infections
Submission type
Non submission
Status
Not recommended
Date advice published
15 January 2018